Revisiting p53 for cancer-specific chemo- and radiotherapy

References

• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57 - 70; http://dx.doi.org/10.1016/S0092-8674(00)81683-9; PMID: 10647931
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002; 297:63 - 4; http://dx.doi.org/10.1126/science.1073096; PMID: 12098689
   PubMed Web of Science ®Google Scholar
• Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136:823 - 37; http://dx.doi.org/10.1016/j.cell.2009.02.024; PMID: 19269363
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr.. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689 - 98; http://dx.doi.org/10.1038/nrc1691; PMID: 16110319
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913 - 7; http://dx.doi.org/10.1038/nature03443; PMID: 15829966
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917 - 21; http://dx.doi.org/10.1038/nature03445; PMID: 15829967
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49 - 53; http://dx.doi.org/10.1126/science.1905840; PMID: 1905840
   PubMed Web of Science ®Google Scholar
• Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006; 6:55 - 61; http://dx.doi.org/10.1517/14712598.6.1.55; PMID: 16370914
   PubMed Web of Science ®Google Scholar
• Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9:93 - 101; PMID: 12538456
   PubMed Web of Science ®Google Scholar
• Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer?. Lancet Oncol 2003; 4:415 - 22; http://dx.doi.org/10.1016/S1470-2045(03)01139-2; PMID: 12850192
   PubMed Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862 - 73; http://dx.doi.org/10.1038/nrc2763; PMID: 19935675
   PubMed Web of Science ®Google Scholar
• Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11:175 - 89; http://dx.doi.org/10.1016/j.ccr.2006.11.024; PMID: 17292828
   PubMed Web of Science ®Google Scholar
• Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, Couvillon AD, Jacks T, Yaffe MB. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep 2013; 5:868 - 77; http://dx.doi.org/10.1016/j.celrep.2013.10.025; PMID: 24239348
   PubMed Web of Science ®Google Scholar
• Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009; 8:3112 - 9; http://dx.doi.org/10.4161/cc.8.19.9626; PMID: 19755856
   PubMed Web of Science ®Google Scholar
• Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, Tokarz M, Adams BR, Wagner AF, Khalil A, Gilfor D, et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res 2013; 19:3189 - 200; http://dx.doi.org/10.1158/1078-0432.CCR-12-3408; PMID: 23620409
   PubMed Web of Science ®Google Scholar
• Raman M, Earnest S, Zhang K, Zhao Y, Cobb MH. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 2007; 26:2005 - 14; http://dx.doi.org/10.1038/sj.emboj.7601668; PMID: 17396146
   PubMed Web of Science ®Google Scholar
• Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H, Kalita O, Kolar Z, Poulsen HS, Broholm H, et al. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010; 29:5095 - 102; http://dx.doi.org/10.1038/onc.2010.249; PMID: 20581868
   PubMed Web of Science ®Google Scholar
• Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64:9152 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-04-2727; PMID: 15604286
   PubMed Web of Science ®Google Scholar
• Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NM, Lau A, Newell DR, Curtin NJ. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Ther 2013; 12:959 - 67; http://dx.doi.org/10.1158/1535-7163.MCT-12-0707; PMID: 23512991
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle 2005; 4:269 - 78; http://dx.doi.org/10.4161/cc.4.2.1493; PMID: 15655345
   PubMed Web of Science ®Google Scholar
• van Leeuwen IM. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget 2012; 3:596 - 600; PMID: 22711025
   PubMed Web of Science ®Google Scholar
• Rao B, Lain S, Thompson AM. p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy. Br J Cancer 2013; 109:2954 - 8; http://dx.doi.org/10.1038/bjc.2013.702; PMID: 24231949
   PubMed Web of Science ®Google Scholar
• Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012; 149:780 - 94; http://dx.doi.org/10.1016/j.cell.2012.03.031; PMID: 22579283
   PubMed Web of Science ®Google Scholar
• Stürzbecher HW, Donzelmann B, Henning W, Knippschild U, Buchhop S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J 1996; 15:1992 - 2002; PMID: 8617246
   PubMed Web of Science ®Google Scholar
• Sengupta S, Linke SP, Pedeux R, Yang Q, Farnsworth J, Garfield SH, Valerie K, Shay JW, Ellis NA, Wasylyk B, et al. BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J 2003; 22:1210 - 22; http://dx.doi.org/10.1093/emboj/cdg114; PMID: 12606585
   PubMed Web of Science ®Google Scholar
• Kumari A, Schultz N, Helleday T. p53 protects from replication-associated DNA double-strand breaks in mammalian cells. Oncogene 2004; 23:2324 - 9; http://dx.doi.org/10.1038/sj.onc.1207379; PMID: 14743204
   PubMed Web of Science ®Google Scholar
• Saintigny Y, Rouillard D, Chaput B, Soussi T, Lopez BS. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. Oncogene 1999; 18:3553 - 63; http://dx.doi.org/10.1038/sj.onc.1202941; PMID: 10380877
   PubMed Web of Science ®Google Scholar
• Bertrand P, Rouillard D, Boulet A, Levalois C, Soussi T, Lopez BS. Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. Oncogene 1997; 14:1117 - 22; http://dx.doi.org/10.1038/sj.onc.1200931; PMID: 9070661
   PubMed Web of Science ®Google Scholar
• Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, Valerie K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 2007; 67:1046 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-06-2371; PMID: 17283137
   PubMed Web of Science ®Google Scholar
• Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Menon MB, Walter D, Sørensen CS, et al. Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci U S A 2013; 110:16856 - 61; http://dx.doi.org/10.1073/pnas.1304355110; PMID: 24082115
   PubMed Web of Science ®Google Scholar
• Dever SM, White ER, Hartman MC, Valerie K. BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies. Cell Cycle 2012; 11:687 - 94; http://dx.doi.org/10.4161/cc.11.4.19212; PMID: 22306997
   PubMed Web of Science ®Google Scholar
• Dever SM, Golding SE, Rosenberg E, Adams BR, Idowu MO, Quillin JM, Valerie N, Xu B, Povirk LF, Valerie K. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination. Aging (Albany NY) 2011; 3:515 - 32; PMID: 21666281
   PubMedGoogle Scholar
• Feng Z, Kachnic L, Zhang J, Powell SN, Xia F. DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem 2004; 279:28574 - 84; http://dx.doi.org/10.1074/jbc.M404137200; PMID: 15087457
   PubMed Web of Science ®Google Scholar
• Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, et al. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res 2011; 71:5546 - 57; http://dx.doi.org/10.1158/0008-5472.CAN-10-3423; PMID: 21742769
   PubMed Web of Science ®Google Scholar
• Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O’Connor MJ, Valerie K. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle 2012; 11:1167 - 73; http://dx.doi.org/10.4161/cc.11.6.19576; PMID: 22370485
   PubMed Web of Science ®Google Scholar
• Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 2009; 8:2894 - 902; http://dx.doi.org/10.1158/1535-7163.MCT-09-0519; PMID: 19808981
   PubMed Web of Science ®Google Scholar